MedTrace Logo

Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity

NCT06720766 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-12-06

No results posted yet for this study

Summary

The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity.

The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.

Conditions

  • Fatty Liver Disease

Interventions

DIAGNOSTIC_TEST

FibbroScan and biopsy

In individuals with obesity, a biopsy is performed within a week after undergoing an FibroScan examination.

Sponsors & Collaborators

  • The Third People's Hospital of Chengdu

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-24
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06720766 on ClinicalTrials.gov